Skip to main content

Novel Rx

      Factors Associated with Poor Vaccine Response in Rituximab: Dr. Yuzaiful Yusof (@Yuz6Yusof) discusses abstract #0437 pre

      Dr. John Cush RheumNow

      3 years 6 months ago
      Factors Associated with Poor Vaccine Response in Rituximab: Dr. Yuzaiful Yusof (@Yuz6Yusof) discusses abstract #0437 presented at the #ACR21 annual meeting. https://t.co/T0PFiZlbTa https://t.co/idj5T7j7ke
      RT @RichardPAConway: Comparative risks of skin SCC and BCC with different DMARDs. Abatacept appeared worst, HR 2.18, but

      Richard Conway RichardPAConway

      3 years 6 months ago
      Comparative risks of skin SCC and BCC with different DMARDs. Abatacept appeared worst, HR 2.18, but may be residual confounding due to burden disease/comorbidities. Abstr#1942 #ACR21 @RheumNow https://t.co/UzOwuKKFmX
      RT @Janetbirdope: Who declines most with #scleroderma #ILD - early dcSSc, ⬆️CRP, ⬆️mRSS all w more ⤵️FVC. Re

      Janet Pope Janetbirdope

      3 years 6 months ago
      Who declines most with #scleroderma #ILD - early dcSSc, ⬆️CRP, ⬆️mRSS all w more ⤵️FVC. Results verified in SENSIS trial of SSc ILD where #nintedanib was superior to placebo abst#1846 #ACR21 @RheumNow https://t.co/eckUj0qwch
      RT @doctorRBC: Should we be measuring drug levels in pts taking infliximab?
      ⭐️Drug monitoring vs. standard dosing sh

      Robert B Chao, MD doctorRBC

      3 years 6 months ago
      Should we be measuring drug levels in pts taking infliximab? ⭐️Drug monitoring vs. standard dosing showed 73% sustained control vs. 55% (RA, PsA, SpA, UC, Crohn's, PsO) #ACR21 Abs#1946 #ACRBest @RheumNow https://t.co/sWMen50ljP https://t.co/F4Wpqis3id
      RT @Janetbirdope: OK is this a swan or a swan song? Graph looks like a swan 🦢 but message is NO #MACE differences in

      Janet Pope Janetbirdope

      3 years 6 months ago
      OK is this a swan or a swan song? Graph looks like a swan 🦢 but message is NO #MACE differences in PsA on csDMARDs v #biologics #ACR21 abst#1833 @RheumNow https://t.co/TM91z5wiFY
      RT @Janetbirdope: So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different

      Janet Pope Janetbirdope

      3 years 6 months ago
      So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different w or without #MTX. Abst#L12 @RheumNow #ACR21 https://t.co/Zp5owTpLvm
      RT @EBRheum: Important late breaker @TerrierBen, DBRCT of RTX vs GC (FFS=0) or CYC (FFS>0) for EGPA

      RTX not superior

      Mike Putman EBRheum

      3 years 6 months ago
      Important late breaker @TerrierBen, DBRCT of RTX vs GC (FFS=0) or CYC (FFS>0) for EGPA RTX not superior to CYC (64% RTX vs 60% CYC BVAS remission d180, p = 0.745); similar in subgroups Feel like this lends support to (~surprising) ACR/VF recs for EGPA? #ACR21 #ACRAmbassador https://t.co/gpsPtXF6pj
      RT @ericdeinmd: #ACR21 L19: TitAIN: Secukinumab for GCA
      ⭐️Phase 2 study with n=52
      ⭐️70% of SEC sustained remissi

      Eric Dein ericdeinmd

      3 years 6 months ago
      #ACR21 L19: TitAIN: Secukinumab for GCA ⭐️Phase 2 study with n=52 ⭐️70% of SEC sustained remission at wk 28 vs 20% PBO, 59% at week 52 vs 8% ⬇️Cumulative prednisolone through wk 52 (2.8g v 3.4g) - Looking forward to larger study @Rheumnow https://t.co/cuM9LcEr4u https://t.co/TmyS0kixFg
      RT @ericdeinmd: #ACR21 L21. REOVAS: RTX for EGPA
      ⭐️CYC traditionally preferred for 5-factor score>0
      ▶️Remissi

      Eric Dein ericdeinmd

      3 years 6 months ago
      #ACR21 L21. REOVAS: RTX for EGPA ⭐️CYC traditionally preferred for 5-factor score>0 ▶️Remission rates and relapse-free survival comparable bw RTX and conventional. RTX not superior for induction ▶️No diff in ANCA+/-, naive v relapse, FFS https://t.co/cuM9LcEr4u @Rheumnow
      RT @uptoTate: Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use

      Dr. Rachel Tate uptoTate

      3 years 6 months ago
      Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use in Caucasians w/ PsA vs DMARDs in black PsA pts. View Abs 1780 for other relevant findings. #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/0uKsa8i0bG https://t.co/R9YkxYqXws
      ×